Prophylactic Options News Today

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

October 2, 2013 at 9:00 AM EDT Research to focus on antibody production for immune defense CAMBRIDGE, Mass., October 2, 2013—Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the  in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid ...